CoALL 2020 Registry

Author: J. Dobke, Last modification: 2024/04/12 https://kinderkrebsinfo.de/doi/e230668

CoALL 2020 Registry	CoALL 2020 Registry for the diagnostic, treatment and follow-up of acute lymphoblastic leukemia, T- and B-precursor Non-Hodgkin lymphoma in children and adolescents
Disease	Acute lyphoblastic leukemia, T- and B-precursor Non-Hodgkin lymphomas
Type	Registry
Rationale / Objectives	The register collects person- and disease-specific data from children and adolescents who are treated in study centres of the former CoALL 08-09 study due to newly diagnosed ALL, T-NHL or B-precursor NHL. Disease-related data on the biology and the course of the disease are collected. Objectives Recording of all ALL as well as T- and B-precursor NHL diseases and their treatment in children and adolescents in the participating centres. Recording of the morphological, cytogenetic, molecular genetic as well as immunophenotypic characteristics of ALL and T-/B-precursor NHL in children at the initial diagnosis and in the course of therapy. Recording of the treatment response by minimal residual disease (MRD) during the course of therapy. Recording the frequency of (molecular) relapse. Determination of the overall survival and event-free survival. Analysis of the influence of MRD-based risk classification and therapeutical decisions on overall survival and event-free survival in a historical comparison
Therapy / Study arms	The registry does not provide any specific treatment recommendations. Patients should be treated according to an established standard therapy currently applicable in Germany. The study centre also advises on individual therapy strategies in individual cases.
Inclusion Criteria	Primary acute lymphoblastic leukemia (ALL) or ALL as a second malignancy or Acute biphenotypical leukemia (after consultation and approval by the Study coordination centre) or Acute undifferentiated leukemia (after consultation and approval by the Study coordination centre) or Non-Hodgkin Lymphomas: T-NHL or B-precursor-NHL, if ther is no participation in the LBL 2018 study or „special“ cases of ALL-associated diseases (after consultation and approval by the Study coordination centre) or ALL relapse without participation in one of the IntReALL studies Age at diagnosis < 18 or >= 18 (after consultation and approval by the Study coordination centre Admission to an accredited paediatric oncology centre in accordance with the GBA decision "Paediatric Oncology" Consent of the patient and legal representative
Exclusion Criteria	Missing consent of the patient and/or the legal representative Patient with primary ALL with Philadelphia-Chromosome (BCR/ABL)
Recruitment	unlimited
Status	Start 01/01/2020; End 31/12/2030
Principal Investigator	PD Dr. med. G. Escherich
E-Mail	escherich@uke.de
URL	https://www.uke.de/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/forschung/arbeitsgruppen/coall-studie.html
Contact	Coordinator PD Dr. med. Gabriele Escherich Universitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik f. Päd. Hämatologie u. Onkologie Martinistraße 52 20246 Hamburg Telefon +49 (40) 42803 3796 / 74 10- 5 2580 Fax +49 (40) 42803 3608 escherich@uke.uni-hamburg.de Documentation Kseniya Bakharevich Universitätsklinikum Hamburg-Eppendorf Klinik für Pädiatrische Hämatologie und Onkologie Martinistr. 52 20246 Hamburg Telefon +49 (0)40 7410 52580 Fax +49 (0)40 7410 58101 k.bakharevich@uke.de
Participants	6 centres in Germany: Evangelisches Klinikum Bethel Bielefeld, Universitätsklinikum Bonn, Klinikum Bremen-Mitte, Universitätsklinikum Hamburg Eppendorf, Helios Klinikum Krefeld, Universitätsmedizin Mainz